aiwiki.page
English
Health / Diseases & Symptoms / iron-overload

Iron overload

Iron overload is excessive accumulation of body iron caused by inherited regulatory defects, repeated transfusions, or other acquired conditions, potentially damaging multiple organs.

44 keywords2 linked from8 not yet writtenWritten by AI
Blood Transfusio…MetabolismThalassemiaInflammationMagnetic Resonan…Bone MarrowFerritinDNAIron overl…

Iron overload is the accumulation of iron in the body beyond normal physiological requirements and storage capacity. It can result from excessive intestinal absorption, repeated blood transfusions, or certain disorders of blood formation and iron handling. Iron is essential for oxygen transport and cellular metabolism, but excess iron can generate chemically reactive molecules that damage tissues. The liver, heart, and endocrine organs are particularly vulnerable.

Iron overload is a physiological and pathological state rather than a single disease. Hereditary hemochromatosis is an important inherited cause, whereas transfusion-dependent thalassemia and other chronic anemias are major acquired settings. An elevated blood ferritin concentration alone does not establish iron overload: ferritin also rises with inflammation, liver injury, and several metabolic conditions.

Assessment therefore distinguishes the cause of iron accumulation, the quantity and distribution of stored iron, and any resulting organ damage. Blood measurements, genetic testing, and magnetic resonance imaging provide complementary information. Treatment removes iron through blood removal or iron-binding medicines, with the method determined principally by whether normal red-cell production can be maintained.

Normal iron balance and the mechanisms of overload

An adult body usually contains approximately 3–4 g of iron, although the amount varies with body size, hemoglobin concentration, and iron stores. Most is incorporated into hemoglobin in red blood cells; smaller amounts occur in muscle myoglobin, iron-dependent enzymes, and storage proteins. Only about 1–2 mg normally enters the body through intestinal absorption each day, balancing small losses through shed cells, sweat, and bleeding. Humans have no regulated pathway capable of excreting large quantities of excess iron.

Most iron needed for daily red-cell production is therefore recycled rather than newly absorbed. Macrophages remove aging red cells and recover their iron, returning roughly 20–25 mg daily to the circulating iron pool in a typical adult. Transferrin, the principal plasma iron-transport protein, carries iron to developing red cells in the bone marrow and to other tissues. Inside cells, ferritin stores iron in a relatively protected form. Larger or less readily mobilized deposits may appear as hemosiderin, an iron-containing material identifiable in tissue sections.

The central hormonal regulator is hepcidin, a small peptide produced mainly by the liver. Hepcidin binds to ferroportin, the major cellular iron exporter, reducing iron release from intestinal cells, macrophages, and storage sites. Higher iron availability normally stimulates hepcidin production, restricting further absorption and release. Increased demand for red-cell production has the opposite effect. Inflammation also stimulates hepcidin, explaining why some inflammatory illnesses produce low circulating iron despite adequate or increased stores.

Iron overload develops when this control system is bypassed or becomes insufficient. In common forms of hereditary hemochromatosis, hepcidin activity is inappropriately low for the amount of stored iron, or ferroportin is resistant to it. Intestinal absorption therefore continues despite expanding stores. Transfusions create a different problem: their iron enters directly in donor red cells, beyond the intestine’s regulatory control. Each unit of packed red cells introduces approximately 200–250 mg of iron.

As transferrin becomes increasingly saturated, iron can appear in plasma in forms collectively called non-transferrin-bound iron. A redox-active component, often termed labile plasma iron, can enter susceptible tissues and promote oxidative stress. Ferrous iron participates in the Fenton reaction:

Fe2++H2O2→Fe3++OH−+⋅OH.\mathrm{Fe^{2+} + H_2O_2 \rightarrow Fe^{3+} + OH^- + {\cdot}OH}.

The hydroxyl radical generated by this reaction can damage lipids, proteins, and DNA. Cellular defenses buffer some excess iron, but prolonged exposure can exceed their capacity.

Inherited disorders of iron regulation

The most familiar inherited form of iron overload is HFE-related hemochromatosis, an usually adult-onset disorder associated particularly with homozygosity for the HFE p.Cys282Tyr variant, commonly abbreviated C282Y. The HFE protein participates in liver iron sensing and regulation of hepcidin production. Reduced signaling allows iron absorption to remain higher than physiological requirements over many years. The disorder is generally inherited in an autosomal recessive pattern, but its expression is strongly variable.

A disease-associated genotype is not equivalent to clinically important iron overload. Some C282Y homozygotes develop elevated transferrin saturation without substantial tissue injury; others accumulate enough iron to develop organ disease. Age, sex, blood loss, alcohol exposure, and coexisting liver disease influence the phenotype. Men commonly develop substantial loading earlier than women. Menstrual and reproductive iron losses help explain part of this difference, although they do not account for all variation. The HFE p.His63Asp variant, or H63D, has much lower disease penetrance and should not by itself be treated as proof of iron-loading disease.

Rare inherited disorders can produce earlier and more severe accumulation. Pathogenic variants in HJV, which encodes hemojuvelin, or in HAMP, which encodes hepcidin itself, cause severe hepcidin deficiency. These disorders have traditionally been grouped as juvenile hemochromatosis because they often present in adolescence or early adulthood, sometimes with prominent cardiac or endocrine disease. TFR2-related hemochromatosis disrupts another component of iron sensing. Its presentation varies, but substantial loading may occur earlier than in typical HFE-related disease.

Variants in SLC40A1, the gene encoding ferroportin, require a mechanistic distinction. Some impair iron export and cause iron retention predominantly in macrophages. This classical ferroportin disease often produces high ferritin with normal or relatively low transferrin saturation, and blood removal may be limited by the development of anemia. Other variants make ferroportin resistant to hepcidin, producing increased circulating iron and parenchymal loading more similar to hepcidin-deficient hemochromatosis.

Other rare genetic conditions combine iron accumulation with neurological or hematological abnormalities. Aceruloplasminemia, caused by defects in the ceruloplasmin gene, can lead to systemic and brain iron accumulation, diabetes, and neurological disease. Severe transferrin deficiency can produce the apparently paradoxical combination of anemia and tissue iron overload. These conditions illustrate why an inherited iron disorder cannot always be classified from ferritin or ancestry alone: the affected transport pathway determines where iron accumulates and whether circulating iron is high or low.

Transfusional and other acquired causes

Repeated red-cell transfusion is a major cause of clinically significant iron overload. Transfused erythrocytes eventually undergo normal breakdown, but their iron remains in the recipient unless removed by bleeding or treatment. After approximately 20 units, several grams of additional iron may have entered the body. The transfusion burden at which organ risk becomes important varies with body size, underlying disease, baseline stores, and the duration of exposure.

Transfusional overload occurs in transfusion-dependent thalassemia, sickle cell disease, myelodysplastic syndromes, and some forms of marrow failure, including aplastic anemia. It can also persist after successful hematopoietic stem-cell transplantation, when the original hematological disorder has been corrected but accumulated iron remains. Patterns of extrahepatic loading differ among these diseases. For example, cardiac iron accumulation is generally less frequent in sickle cell disease than in comparably transfused thalassemia populations, although severe hepatic iron loading can occur in both.

Ineffective red-cell production provides an additional mechanism. In several thalassemia syndromes, the marrow produces large numbers of abnormal erythroid precursors, many of which fail to mature. Erythroid signaling, including increased erythroferrone production, suppresses hepcidin and increases intestinal iron absorption. Consequently, people with non-transfusion-dependent thalassemia can accumulate clinically important iron without regular transfusions. Related mechanisms operate in some congenital dyserythropoietic and sideroblastic anemias. When transfusions are also given, increased absorption and transfusional iron can act together.

Chronic liver disorders may be accompanied by abnormal iron measurements or actual hepatic iron deposition. Alcohol exposure can alter hepcidin regulation and iron absorption, while liver-cell injury releases ferritin into the circulation. Metabolic dysfunction-associated steatotic liver disease frequently causes increased ferritin; only a subset of affected individuals has a substantial increase in tissue iron. Thus, metabolic hyperferritinemia and iron overload overlap but are not interchangeable diagnoses. Chronic hepatitis C and other liver diseases can also modify iron distribution and blood measurements.

Excessive medicinal iron exposure is another possible cause, particularly when parenteral iron is repeatedly administered beyond replacement needs. Historically, dietary iron overload was described in parts of sub-Saharan Africa in association with consumption of traditional beer containing substantial iron acquired during preparation in iron vessels; susceptibility was not explained by exposure alone. Acute ingestion of a large amount of iron is a different clinical entity, characterized by direct gastrointestinal and systemic toxicity rather than the slowly progressive storage disorder discussed here. Ordinary dietary iron intake does not usually produce major systemic overload when regulation is intact.

Tissue injury and clinical manifestations

The clinical effects of iron overload depend on cumulative exposure, the chemical availability of iron, tissue distribution, and coexisting disease. A large iron store does not necessarily cause immediate symptoms, and early overload is often detected before organ dysfunction develops. Fatigue, weakness, and nonspecific abdominal discomfort can occur, but none reliably distinguishes iron overload from other conditions. The historically described combination of skin pigmentation, diabetes, and cirrhosis represents advanced disease rather than a necessary diagnostic pattern.

The liver is a major storage organ and a central target of injury. Excess iron promotes hepatocellular damage and activates pathways leading to fibrosis. Progressive scarring may culminate in cirrhosis, particularly when other injuries, such as alcohol-associated disease or viral hepatitis, coexist. Advanced fibrosis and cirrhosis substantially increase the risk of hepatocellular carcinoma. Iron removal can improve biochemical abnormalities and may permit regression of fibrosis in some circumstances, but established cirrhosis remains clinically important even after iron stores have been reduced.

Cardiac iron accumulation can disrupt both contractile function and electrical conduction. Manifestations include rhythm disturbances and heart failure, with early diastolic dysfunction sometimes preceding more obvious systolic impairment. Severe myocardial loading is especially important in transfusion-dependent thalassemia and juvenile hemochromatosis. Total liver iron does not reliably predict myocardial iron in an individual, because organs accumulate and clear iron at different rates. This discordance explains the importance of direct cardiac assessment in susceptible populations.

Endocrine injury can affect the pancreas, pituitary gland, thyroid, and other organs. Pancreatic iron and associated metabolic changes may contribute to diabetes mellitus. Pituitary injury can impair gonadotropin secretion, causing delayed puberty, reduced sex-hormone production, menstrual disturbance, or reduced fertility. Growth impairment and reduced bone mass are important complications in chronically affected children and adults, although the underlying anemia, other endocrine abnormalities, and treatment-related factors may also contribute. Osteoporosis in these populations is therefore often multifactorial.

Joint disease is particularly characteristic of hereditary hemochromatosis. The second and third metacarpophalangeal joints are commonly affected, and calcium pyrophosphate crystal deposition may occur. Joint symptoms can persist despite successful reduction of iron stores, unlike some reversible biochemical or cardiac changes. Excess available iron also favors particular microorganisms. Severe infections with organisms such as Vibrio vulnificus and Yersinia enterocolitica have been associated with iron-loading disorders; some iron chelators can additionally alter microbial access to iron. These associations are specific complications, not evidence that every person with elevated ferritin has generalized immune failure.

Blood measurements, genetic testing, and diagnostic interpretation

The initial biochemical assessment commonly includes serum ferritin and transferrin saturation. Ferritin is a useful biomarker of iron stores, but it is also an acute-phase reactant and may rise markedly during inflammation, infection, malignancy, or liver-cell injury. Its concentration therefore does not provide a direct measurement of total-body iron. Conversely, iron overload can be present before ferritin becomes extremely high, particularly when transferrin saturation is already increased.

Transferrin saturation estimates the proportion of transferrin iron-binding sites occupied by iron. It is usually calculated as:

Transferrin saturation (%)=serum irontotal iron-binding capacity×100,\text{Transferrin saturation (\%)}= \frac{\text{serum iron}}{\text{total iron-binding capacity}}\times 100,

with compatible units for numerator and denominator. Persistently increased saturation, often assessed using a threshold around 45%, can indicate increased circulating iron availability and is an important clue to hepcidin-deficient hemochromatosis. However, serum iron varies, and low transferrin concentrations in advanced liver disease can increase calculated saturation without establishing a hereditary disorder. Fasting is not uniformly required by contemporary diagnostic pathways.

Interpretation depends on the combination of findings rather than a single cutoff. The 2022 European Association for the Study of the Liver guideline describes biochemical patterns suggestive of hemochromatosis using transferrin saturation above 45% and ferritin above 200 µg/L in women, and saturation above 50% with ferritin above 300 µg/L in men and postmenopausal women. These values are diagnostic-context thresholds, not universal boundaries between harmless and harmful iron stores. In an appropriate setting, C282Y homozygosity together with the characteristic biochemical pattern can establish HFE-related disease; other genetic patterns generally require clearer evidence of tissue iron loading.

The medical history supplies essential causal information: cumulative transfusions, medicinal iron exposure, family history, alcohol exposure, and known hematological or liver disease. A complete blood count, liver biochemical tests, and markers of inflammation help interpret the iron measurements. The differential diagnosis of high ferritin includes inflammatory and metabolic conditions without substantial iron excess. A particularly instructive rare example is hereditary hyperferritinemia-cataract syndrome, in which ferritin production is increased but systemic iron loading is absent.

Genetic testing is most informative when interpreted alongside the phenotype. Finding one HFE variant does not establish disease, and a negative common-variant test does not exclude a rare inherited iron disorder. Broader testing may identify variants in iron-regulatory genes, but uncertain variants require careful interpretation. Genetic counseling addresses inheritance and implications for relatives. Assessment of adult first-degree relatives is established practice after a well-defined hereditary diagnosis, whereas population-wide genetic screening raises separate questions about penetrance, cost, and overdiagnosis.

Imaging and tissue assessment

Magnetic resonance imaging has largely replaced repeated liver biopsy for quantifying iron in many clinical settings. Iron alters the local magnetic environment and accelerates decay of the MRI signal. Methods measure relaxation parameters such as T2T_2 and T2∗T_2^*, or their reciprocal rates, R2R_2 and R2∗R_2^*. When relaxation time is expressed in seconds,

R2∗=1T2∗.R_2^*=\frac{1}{T_2^*}.

Greater iron loading generally shortens T2T_2 or T2∗T_2^* and increases the corresponding relaxation rate. Validated calibration methods convert these measurements into estimates of liver iron concentration.

Liver iron concentration is commonly reported in milligrams of iron per gram of dry liver tissue. A value around 1.8 mg/g dry weight is often used as an upper reference boundary, although reference ranges and analytical conventions vary. The clinical meaning of higher concentrations depends on the disease and duration of loading; risk is not defined by one universally applicable number. MRI estimates are method-dependent, and serial measurements are most interpretable when obtained with validated techniques and consistent acquisition and analysis procedures. Severe loading, fat, and technical factors can complicate measurement.

Cardiac T2∗T_2^* imaging assesses myocardial iron directly. At a magnetic field strength of 1.5 tesla, a myocardial T2∗T_2^* below approximately 20 milliseconds is widely used as evidence of cardiac iron, while values below 10 milliseconds identify more severe loading and greater cardiac risk in studied thalassemia populations. These thresholds belong to a particular measurement context and are not automatically transferable to every scanner or sequence. Cardiac function and symptoms provide additional information, because iron deposition can precede functional deterioration.

Liver biopsy remains useful when tissue examination is needed to clarify another liver disorder, investigate an uncertain diagnosis, or assess fibrosis in selected circumstances. Chemical analysis can measure tissue iron directly, while histopathological examination reveals its cellular distribution. In classic hemochromatosis, iron initially accumulates predominantly in hepatocytes, especially near portal tracts. Transfusional loading often begins prominently in macrophages and reticuloendothelial tissues, with parenchymal deposition increasing as overload advances. Perls’ Prussian blue stain demonstrates ferric iron deposits but is not a precise substitute for quantitative analysis.

Assessment of liver damage is distinct from measurement of iron. Elastography and blood-based fibrosis indices can contribute to fibrosis staging, while conventional imaging identifies structural complications. Computed tomography may show increased liver attenuation with heavy iron deposition, but it is not the preferred quantitative monitoring method because of limited specificity and radiation exposure. Neither a normal-looking liver on routine imaging nor a single reassuring ferritin value excludes clinically relevant iron in another organ.

Iron removal by phlebotomy and red-cell apheresis

Therapeutic phlebotomy, also called venesection, removes iron by removing red blood cells. The marrow then uses stored iron to replace them. It is the established treatment for most people with clinically expressed HFE-related hemochromatosis who can maintain adequate hemoglobin production. Unlike an iron-binding drug, phlebotomy does not require chemical processing of iron or excretion of a drug–iron complex.

A typical 500 mL blood removal eliminates approximately 200–250 mg of iron, depending mainly on the hemoglobin concentration. Treatment commonly has an initial depletion phase followed by a maintenance phase, because the underlying tendency to absorb excess iron persists. Depletion schedules in clinical practice are often weekly or every two weeks, but volume and frequency vary with hemoglobin, body size, cardiovascular status, and tolerance. Hemoglobin measurements are used to avoid producing clinically important anemia.

Ferritin is commonly used to follow depletion. The 2022 European guideline identifies a ferritin target around 50 µg/L during induction and approximately 50–100 µg/L during maintenance, while acknowledging differences in tolerability and clinical circumstances. These are supervised treatment targets for a defined disorder, not diagnostic thresholds or general goals for the population. Transferrin saturation may remain elevated after iron stores have been substantially reduced and is not a reliable sole endpoint for continued intensive blood removal.

The strongest rationale for early treatment is prevention of irreversible organ damage. Observational evidence indicates that people treated before cirrhosis and diabetes develop can have survival approaching that of comparable populations. Liver biochemical abnormalities and some functional complications may improve with iron removal. Established arthropathy and endocrine failure are less consistently reversible. When advanced fibrosis or cirrhosis is already present, reducing iron does not necessarily eliminate the subsequent risk of hepatocellular carcinoma, so management of the liver disease remains a separate component of care.

Erythrocytapheresis, a form of apheresis, selectively removes red cells and returns much of the plasma and other blood components. It can remove more red-cell iron per procedure than standard phlebotomy, but requires specialized equipment and vascular access, and its economic and practical advantages vary by setting. Ordinary phlebotomy is generally unsuitable for people whose iron overload accompanies persistent anemia or transfusion dependence, because it removes the oxygen-carrying cells they already lack. After successful correction of a marrow disorder, however, adequate red-cell production may make phlebotomy feasible for residual transfusional iron.

Iron chelation and monitoring of treatment

Iron chelation therapy uses medicines that bind iron and permit its excretion. It is central to treatment when iron accumulation coexists with anemia or continuing transfusion requirements. The three widely used medicines for chronic transfusional overload are deferoxamine, deferiprone, and deferasirox. They differ in route of administration, duration of exposure, tissue distribution, elimination pathways, and adverse-effect profiles. A reduction in circulating or stored iron depends on both the amount removed and the amount continuing to enter the body.

Deferoxamine is usually administered by prolonged subcutaneous infusion, with intravenous administration used in particular settings. It forms a complex with iron that is eliminated through urine and bile. Its short plasma persistence makes duration and consistency of administration important. Long-term use can be complicated by infusion-site reactions and, particularly with excessive exposure relative to iron burden, auditory, ocular, skeletal, or growth-related toxicity. Deferoxamine can also make iron available to certain microorganisms, notably Yersinia, which gives some infections special importance during treatment.

Deferiprone is an oral chelator with an important role in management of myocardial iron. A major safety concern is neutropenia, including potentially life-threatening agranulocytosis, so blood-count surveillance is integral to its use. Other recognized adverse effects include gastrointestinal symptoms, joint symptoms, and increased liver enzymes. Deferasirox is also oral and is eliminated predominantly through the fecal route after binding iron. Important toxicities include renal and hepatic injury and gastrointestinal complications; laboratory monitoring is therefore part of treatment rather than an optional addition.

Some patients receive combined chelation, especially when severe cardiac loading or inadequate control with a single agent creates a need for more intensive iron removal. The evidence and risk–benefit balance differ among combinations and disease settings. Chelators are not interchangeable simply because they all bind iron. Their effectiveness depends on sustained exposure, tissue access, dose, tolerability, and the patient’s ongoing transfusion burden. Complex administration schedules and adverse effects can make sustained treatment difficult.

Monitoring combines serial ferritin, quantitative liver MRI, cardiac MRI where appropriate, and assessment of organ function and drug toxicity. Ferritin trends are more informative than isolated values, but may still diverge from changes in tissue iron. Liver iron can improve while myocardial iron remains elevated, or the reverse, so one compartment cannot stand in for all others. As iron burden declines, continued intensive chelation can create toxicity from overchelation. Clinical evidence is strongest in transfusion-dependent thalassemia; in conditions such as myelodysplastic syndromes, interpretation also depends on comorbidity, competing risks, expected transfusion exposure, and the distinction between improved iron measurements and demonstrated clinical benefit.

Epidemiology, historical development, and continuing research

The frequency of iron overload depends strongly on its cause and the population examined. HFE C282Y homozygosity occurs in roughly 1 in 200–300 people in some populations of northern European ancestry, but is much less common in many other populations. Clinically important disease is less frequent than the genotype because penetrance is incomplete. Estimates vary with age, sex, the definition of disease, and whether a study measures biochemical abnormalities, documented organ injury, or diagnosed hemochromatosis. Genotype frequency therefore cannot be used directly as the prevalence of iron-related organ disease.

Transfusional overload follows a different geographical pattern. Its burden reflects the distribution of inherited anemias, survival with chronic hematological disease, and access to safe transfusion and chelation. Thalassemia is especially important in populations originating from the Mediterranean region, the Middle East, South Asia, and Southeast Asia, although migration has made care increasingly international. Improved survival has also increased the importance of long-term endocrine, hepatic, and cardiac complications. Availability of MRI and continuous access to chelation materially affect whether excess iron is detected and controlled before severe injury develops.

The clinical syndrome was recognized before its molecular basis was understood. In 1889, Friedrich Daniel von Recklinghausen introduced the term “hemochromatosis” in describing iron-containing pigmentation and associated disease. The condition was long recognized through late manifestations such as cirrhosis, diabetes, and skin pigmentation. Wider use of therapeutic blood removal during the twentieth century established that the iron burden itself could be reduced. Identification of HFE in 1996 transformed investigation of the common inherited form, while discovery of hepcidin around 2000 and subsequent work on its interaction with ferroportin provided a unifying physiological mechanism.

The introduction of long-term chelation changed the natural history of transfusion-dependent thalassemia. Later development of quantitative cardiac MRI made it possible to detect myocardial iron before overt heart failure and to assess treatment effects directly in the heart. This represented an important shift from relying primarily on ferritin or liver iron as indirect indicators of cardiac risk. Improved transfusion practice, chelation, imaging, and specialist care have acted together, so changes in survival cannot be attributed to one measurement or medicine alone.

Current research includes hepcidin mimetics, ferroportin inhibitors, and other approaches intended to restrict excessive iron entry into plasma. These strategies address abnormal regulation rather than simply removing accumulated iron. Their effects depend on the underlying disease: restricting iron availability might reduce pathological absorption but can also limit red-cell production if taken too far. Treatments that reduce transfusion requirements, including selected disease-modifying medicines and gene therapies for inherited blood disorders, may reduce future iron input without immediately eliminating existing stores. Remaining questions include how best to predict progression in genetically susceptible individuals, measure biologically toxic iron, and connect changes in laboratory or imaging endpoints with long-term organ outcomes.